Sally Clive
YOU?
Author Swipe
View article: A prospective national precision medicine trial comparing blood and tissue profiling in patients with Cancer of Unknown Primary (CUPCOMP)
A prospective national precision medicine trial comparing blood and tissue profiling in patients with Cancer of Unknown Primary (CUPCOMP) Open
Background Cancer of Unknown Primary (CUP) is an aggressive malignancy with limited treatment options and poor patient outcomes. In most cases, the primary site remains elusive, limiting therapeutic options to non-specific chemotherapy. Th…
View article: OD30 Clinician-Driven Health Technology Assessment: National Cancer Medicines Review For Off-Label Uses And On-Label Off-Patent Uses In NHSScotland
OD30 Clinician-Driven Health Technology Assessment: National Cancer Medicines Review For Off-Label Uses And On-Label Off-Patent Uses In NHSScotland Open
Introduction Publicly funded cancer services face significant financial and capacity challenges. It is estimated that 40 percent of medicines used to treat cancer are outside their marketing authorization or “off-label.” These uses are usu…
View article: Biomarkers of systemic inflammation provide additional prognostic stratification in cancers of unknown primary
Biomarkers of systemic inflammation provide additional prognostic stratification in cancers of unknown primary Open
Background Biomarkers of systemic inflammation have been shown to predict outcomes in patients with cancer of unknown primary (CUP). We sought to validate these findings in patients with confirmed CUP (cCUP) and explore their role alongsid…
View article: 2157P A phase II randomised controlled trial comparing the cardiotoxicity of capecitabine and S-1
2157P A phase II randomised controlled trial comparing the cardiotoxicity of capecitabine and S-1 Open
View article: Data from Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunologic and Clinical Outcomes
Data from Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunologic and Clinical Outcomes Open
Purpose: We have clinically evaluated a DNA fusion vaccine to target the HLA-A*0201–binding peptide CAP-1 from carcinoembryonic antigen (CEA605–613) linked to an immunostimulatory domain (DOM) from fragment C of tetanus t…
View article: Supplementary Methods, Table 1 from A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors
Supplementary Methods, Table 1 from A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors Open
PDF file - 99KB, Supplementary Methods: The supplemental material contains additional detail on the pharmacokinetic and pharmacodynamic methods used during the study as well as a summary table of safety events and a figure detailing patien…
View article: Supplementary Figure 1 from A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors
Supplementary Figure 1 from A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors Open
PDF file - 25KB, Supplementary Figure S1. Patient disposition: AE, adverse event. KRAS, Kirsten rat sarcoma-2. PD, progressive disease. q2w, every 2 weeks. q3w, every 3 weeks.
View article: Data from Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunologic and Clinical Outcomes
Data from Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunologic and Clinical Outcomes Open
Purpose: We have clinically evaluated a DNA fusion vaccine to target the HLA-A*0201–binding peptide CAP-1 from carcinoembryonic antigen (CEA605–613) linked to an immunostimulatory domain (DOM) from fragment C of tetanus t…
View article: Supplementary Methods, Table 1 from A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors
Supplementary Methods, Table 1 from A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors Open
PDF file - 99KB, Supplementary Methods: The supplemental material contains additional detail on the pharmacokinetic and pharmacodynamic methods used during the study as well as a summary table of safety events and a figure detailing patien…
View article: Supplementary Figures 1-6, Supplementary Tables 1-2 from Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunologic and Clinical Outcomes
Supplementary Figures 1-6, Supplementary Tables 1-2 from Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunologic and Clinical Outcomes Open
Supplementary Figure S1: Detection of CAP-1-specific T-cells Supplementary Figure S2: Effect of CAP-1-specific responses on OS Supplementary Figure S3: Effect of tumor load on vaccine-induced responses Supplementary Figure S4: Discovery of…
View article: Supplementary Figures 1-6, Supplementary Tables 1-2 from Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunologic and Clinical Outcomes
Supplementary Figures 1-6, Supplementary Tables 1-2 from Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunologic and Clinical Outcomes Open
Supplementary Figure S1: Detection of CAP-1-specific T-cells Supplementary Figure S2: Effect of CAP-1-specific responses on OS Supplementary Figure S3: Effect of tumor load on vaccine-induced responses Supplementary Figure S4: Discovery of…
View article: Data from A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors
Data from A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors Open
Purpose: This phase I/II study evaluated safety, efficacy, and pharmacokinetics of escalating, multiple doses of siltuximab, a chimeric anti-interleukin (IL)-6 monoclonal antibody derived from a new Chinese hamster ovary (CHO) cell …
View article: Data from A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors
Data from A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors Open
Purpose: This phase I/II study evaluated safety, efficacy, and pharmacokinetics of escalating, multiple doses of siltuximab, a chimeric anti-interleukin (IL)-6 monoclonal antibody derived from a new Chinese hamster ovary (CHO) cell …
View article: Supplementary Figure 1 from A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors
Supplementary Figure 1 from A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors Open
PDF file - 25KB, Supplementary Figure S1. Patient disposition: AE, adverse event. KRAS, Kirsten rat sarcoma-2. PD, progressive disease. q2w, every 2 weeks. q3w, every 3 weeks.
View article: 426P Assessing nivolumab in class II expressing microsatellite stable (pMMR) colorectal cancer (CRC): Results of the ANICCA-Class II trial
426P Assessing nivolumab in class II expressing microsatellite stable (pMMR) colorectal cancer (CRC): Results of the ANICCA-Class II trial Open
View article: Characterisation and outcomes of patients referred to a regional cancer of unknown primary team: a 10-year analysis
Characterisation and outcomes of patients referred to a regional cancer of unknown primary team: a 10-year analysis Open
View article: Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer
Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer Open
isrctn.org Identifier: ISRCTN44687907.
View article: A biobank analysis of prognostic biomarkers of the systemic inflammatory response in patients presenting with malignancy of undefined primary origin
A biobank analysis of prognostic biomarkers of the systemic inflammatory response in patients presenting with malignancy of undefined primary origin Open
View article: Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial
Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial Open
View article: Designing and evaluating dose-escalation studies made easy: The MoDEsT web app
Designing and evaluating dose-escalation studies made easy: The MoDEsT web app Open
Background/aims: Dose-escalation studies are essential in the early stages of developing novel treatments, when the aim is to find a safe dose for administration in humans. Despite their great importance, many dose-escalation studies use s…
View article: A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424
A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424 Open
AZD0424 displayed no evidence of efficacy as monotherapy despite a clear pharmacodynamic effect. Further evaluation of AZD0424 monotherapy in patients with solid tumours is not recommended.
View article: Embracing model-based designs for dose-finding trials
Embracing model-based designs for dose-finding trials Open
View article: Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunologic and Clinical Outcomes
Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunologic and Clinical Outcomes Open
Purpose: We have clinically evaluated a DNA fusion vaccine to target the HLA-A*0201–binding peptide CAP-1 from carcinoembryonic antigen (CEA605–613) linked to an immunostimulatory domain (DOM) from fragment C of tetanus toxin. Experimental…